Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Safety Triggers Tighten As Senate Continues Work On FDA Revitalization Act

Executive Summary

Provisions that specify which information will trigger the requirement for a drug to have a Risk Evaluation and Mitigation Strategy have been added to the FDA Revitalization Act as Senate floor debate on the bill continues

You may also be interested in...



FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines

Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa

FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines

Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa

Sen. Coburn Plays It Safe; FDA Will Review Medical Marijuana But Not RU-486

A path to federal legalization of state-sanctioned medical marijuana was approved by the Senate Health, Education, Labor and Pensions Committee as part of the markup of a bill renewing FDA's user fee program

Related Content

UsernamePublicRestriction

Register

PS048340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel